BGB324, our first-in-class selective AXL kinase inhibitor, is currently in large-scale Phase 2 clinical testing in North America and Europe. Study investigators are recruiting patients with AML as well as NSCLC and welcome enquiries from potential participants.
If you, or a loved one, are at least 18 years old and are diagnosed with AML and want to learn more about our study please use the following link: Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML.
If you, or a loved one, are at least 18 years old and are diagnosed with stage IV NSCLC and want to learn about our lung cancer trial please follow this link: A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer.
Study investigators welcome enquiries from potential participants.